DK1361439T3 - Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteiner - Google Patents
Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteinerInfo
- Publication number
- DK1361439T3 DK1361439T3 DK02291170T DK02291170T DK1361439T3 DK 1361439 T3 DK1361439 T3 DK 1361439T3 DK 02291170 T DK02291170 T DK 02291170T DK 02291170 T DK02291170 T DK 02291170T DK 1361439 T3 DK1361439 T3 DK 1361439T3
- Authority
- DK
- Denmark
- Prior art keywords
- bcl
- proteins
- inhibit
- peptides
- screening
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02291170A EP1361439B1 (en) | 2002-05-07 | 2002-05-07 | Screening for peptides inhibiting PP1c binding to Bcl-2, BCL-Xl and BCL-W proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1361439T3 true DK1361439T3 (da) | 2007-03-26 |
Family
ID=29225746
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06023212T DK1788394T3 (da) | 2002-05-07 | 2002-05-07 | Screening for peptider, der hæmmer PP1c binding til Bcl-2, BCL-Xl og BCL-W proteiner |
DK02291170T DK1361439T3 (da) | 2002-05-07 | 2002-05-07 | Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteiner |
DK03749894T DK1502116T3 (da) | 2002-05-07 | 2003-05-06 | Screening for peptider, der inhiberer PP1C-binding til BCL-2-, BCL-XL- og BCL-W-proteiner |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06023212T DK1788394T3 (da) | 2002-05-07 | 2002-05-07 | Screening for peptider, der hæmmer PP1c binding til Bcl-2, BCL-Xl og BCL-W proteiner |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03749894T DK1502116T3 (da) | 2002-05-07 | 2003-05-06 | Screening for peptider, der inhiberer PP1C-binding til BCL-2-, BCL-XL- og BCL-W-proteiner |
Country Status (13)
Country | Link |
---|---|
US (2) | US7741288B2 (es) |
EP (4) | EP1361439B1 (es) |
AT (4) | ATE345504T1 (es) |
AU (1) | AU2003242569A1 (es) |
CA (1) | CA2484211A1 (es) |
CY (2) | CY1107367T1 (es) |
DE (4) | DE60232691D1 (es) |
DK (3) | DK1788394T3 (es) |
ES (3) | ES2327773T3 (es) |
HK (3) | HK1062198A1 (es) |
PT (3) | PT1788394E (es) |
SI (1) | SI1502116T1 (es) |
WO (1) | WO2003096022A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT413945B (de) * | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
WO2008137681A2 (en) * | 2007-05-02 | 2008-11-13 | Intrexon Corporation | Pp1 ligands |
EP2348038A1 (de) * | 2010-01-22 | 2011-07-27 | Philipps-Universität Marburg | Verfahren zur Bestimmung der Aktivität der Transglutaminase Faktor XIIIa |
CN106456699B (zh) | 2014-05-05 | 2021-07-02 | 生物风险投资有限责任公司 | 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法 |
WO2015171957A1 (en) * | 2014-05-07 | 2015-11-12 | DOUGLASS, Alyse, N. | Plasmodium liver-stage inhibitors and related methods |
AU2015292710A1 (en) | 2014-07-22 | 2017-02-16 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
CA3018991A1 (en) | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
CN108218962B (zh) * | 2017-12-29 | 2021-06-08 | 广西中医药大学 | 小分子多肽及其用途 |
US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
ATE398287T1 (de) * | 1996-03-30 | 2008-07-15 | Medical Res Council | Wechselwirkungen der katalytischen untereinheit der proteinphosphatase 1 |
JP4544715B2 (ja) * | 1999-08-17 | 2010-09-15 | 成男 太田 | ラットbcl−x遺伝子の改変型cDNAと改変型タンパク質 |
WO2002072601A2 (en) * | 2001-02-07 | 2002-09-19 | The Burnham Institute | Apoptosis modulator bcl-b and methods for making and using same |
AU2002254328A1 (en) * | 2001-03-20 | 2002-10-03 | University Of Chicago | Inhibitors and disassemblers of fibrillogenesis |
US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
-
2002
- 2002-05-07 DE DE60232691T patent/DE60232691D1/de not_active Expired - Lifetime
- 2002-05-07 EP EP02291170A patent/EP1361439B1/en not_active Expired - Lifetime
- 2002-05-07 AT AT02291170T patent/ATE345504T1/de not_active IP Right Cessation
- 2002-05-07 AT AT06023212T patent/ATE434186T1/de not_active IP Right Cessation
- 2002-05-07 DK DK06023212T patent/DK1788394T3/da active
- 2002-05-07 DE DE60216048T patent/DE60216048T2/de not_active Expired - Lifetime
- 2002-05-07 EP EP06023212A patent/EP1788394B1/en not_active Expired - Lifetime
- 2002-05-07 DK DK02291170T patent/DK1361439T3/da active
- 2002-05-07 PT PT06023212T patent/PT1788394E/pt unknown
- 2002-05-07 PT PT02291170T patent/PT1361439E/pt unknown
- 2002-05-07 ES ES06023212T patent/ES2327773T3/es not_active Expired - Lifetime
- 2002-05-07 ES ES02291170T patent/ES2276895T3/es not_active Expired - Lifetime
-
2003
- 2003-05-06 DE DE60318427T patent/DE60318427T2/de not_active Expired - Lifetime
- 2003-05-06 CA CA002484211A patent/CA2484211A1/en not_active Abandoned
- 2003-05-06 EP EP07025179A patent/EP1933150B1/en not_active Expired - Lifetime
- 2003-05-06 DK DK03749894T patent/DK1502116T3/da active
- 2003-05-06 WO PCT/EP2003/005453 patent/WO2003096022A2/en active IP Right Grant
- 2003-05-06 DE DE60333138T patent/DE60333138D1/de not_active Expired - Lifetime
- 2003-05-06 PT PT03749894T patent/PT1502116E/pt unknown
- 2003-05-06 AU AU2003242569A patent/AU2003242569A1/en not_active Abandoned
- 2003-05-06 AT AT03749894T patent/ATE382864T1/de not_active IP Right Cessation
- 2003-05-06 ES ES03749894T patent/ES2300603T3/es not_active Expired - Lifetime
- 2003-05-06 AT AT07025179T patent/ATE472104T1/de not_active IP Right Cessation
- 2003-05-06 SI SI200331166T patent/SI1502116T1/sl unknown
- 2003-05-06 EP EP03749894A patent/EP1502116B1/en not_active Expired - Lifetime
-
2004
- 2004-05-12 HK HK04103329A patent/HK1062198A1/xx not_active IP Right Cessation
- 2004-11-08 US US10/982,891 patent/US7741288B2/en not_active Expired - Fee Related
-
2005
- 2005-07-18 HK HK05106078A patent/HK1078337A1/xx not_active IP Right Cessation
-
2008
- 2008-03-27 CY CY20081100348T patent/CY1107367T1/el unknown
- 2008-12-04 HK HK08113241.2A patent/HK1119249A1/xx not_active IP Right Cessation
-
2009
- 2009-09-17 CY CY20091100963T patent/CY1109383T1/el unknown
-
2010
- 2010-04-06 US US12/755,046 patent/US20110028387A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109383T1 (el) | Σαρωση για πεπτιδια που αναστελλουν την προσδεση της pp1c, στις πρωτεϊνες bcl-2, bcl-xl και bcl-w | |
WO2008043822A3 (en) | Amino acid sequences that bind to a desired molecule in a conditional manner | |
WO2008081701A1 (ja) | Hla-a*1101拘束性wt1ペプチド、およびそれを含む医薬組成物 | |
BRPI0616712B8 (pt) | método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas | |
ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
Schneider et al. | Posttranslational modifications of trichomonad tubulins; identification of multiple glutamylation sites | |
ATE212065T1 (de) | Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung | |
SE9503679D0 (sv) | Antioxidants | |
ATE362487T1 (de) | N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation | |
WO2005044845A3 (en) | Protein binding miniature proteins | |
DK1387854T3 (da) | SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf | |
EA200601749A1 (ru) | Коспептин, космедин и варианты их применения | |
WO2003010184A3 (en) | A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis | |
ATE405827T1 (de) | Screening-verfahren | |
WO2003060067A3 (en) | P85-alpha nucleic acids, polypeptides and related methods | |
WO2005014638A3 (fr) | Peptide interagissant avec les proteines anti-apoptotiques de la famille bcl-2 | |
ATE235509T1 (de) | Peptide zur inhibition von hpv e7 proteinen | |
CA2530731A1 (en) | Peptide having apoptosis-inhibiting activity | |
WO2002074804A3 (en) | Use of binding domains of presenilins and transmembrane proteins for drug screening | |
DE602004021922D1 (de) | Induktion der blütenbildung | |
EP1455186A4 (en) | SCREENING METHOD | |
WO2004013167A3 (en) | Purified polypeptides from enterococcus faecalis | |
WO2004076473A3 (en) | Androgen receptor interacting peptides | |
CY1113998T1 (el) | Πρωτεϊνες που δεσμευουν αλβουμινη ορου | |
CY1111301T1 (el) | Πολυπεπτιδια που προερχονται απο προδρομο πεπτιδιο αμυλοειδους (αρρ) και οι χρησεις αυτων |